Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (106)	5/18/2000 12:41:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 164

CALGARY -- Synsorb Biotech Inc. (SYBB) said it has received a U.S. patent establishing a "firm intellectual property position" in methods for binding Clostridium difficile toxin B and methods of treating diseases in which toxin B may be implicated. In a news release, Synsorb said its current intellectual property position concentrates on the binding of C. difficile toxin A, which is thought to be the principal cause of C. difficile Associated Diarrhea, or CDAD. It said there is increasing evidence that toxin B may play a greater role in the onset of the disease than was previously thought. Synsorb also said it received a notice of allowance on another U.S. patent application containing claims to pharmaceutical composition of matter for treatment of C. difficile toxin B associated conditions. It said CDAD is a common hospital-acquired infection usually associated with antibiotic use, AIDS and chemotherapy.